Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation
BeiGene, Hengrui Head Local R&D Push
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
You may also be interested in...
The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.
The latest approval for AnNiKe (penpulimab) from Akeso/Sino Biopharm adds further competition to a crowded space where six PD-1 immuno-oncology drugs elbow each other.
China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years.